UPDATE: Credit Suisse Upgrades Ironwood Pharmaceuticals to Outperform on Positive Linzess Survey

Credit Suisse upgraded Ironwood Pharmaceuticals

from Neutral to Outperform and raised the price target from $15.00 to $24.00. Credit Suisse analyst Catherine Arnold commented, "CS proprietary market research survey with ~100 physicians implies greater demand via both category expansion and competitive market share. Respondents include 55% gastroenterologists and 45% PCPs, ~70% who were early Linzess users, and all with brand awareness." Ironwood Pharmaceuticals closed at $17.68 on Thursday.